(Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act and cancellation of treasury stock pursuant to the provisions of Article 178 of the Companies Act)
Tokyo, October 31, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.) today announced that at the meeting of the Board of Directors held today, a resolution was adopted to acquire its own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act. The Company also announced that it decided to cancel its treasury stock pursuant to the provisions of Article 178 of the Companies Act.The details are as follows.
- Reasons for the acquisition of own shares
To improve capital efficiency and shareholder return.
- Details of the acquisition of own shares
(1) Class of shares to be acquired: Common stock of the Company
(2) Total number of shares to be acquired: Up to 32 million shares
(Ratio to the total number of shares outstanding [excluding treasury stock]: 1.70 %)
(3) Total amount of acquisition cost: Up to 50 billion yen
(4) Period of acquisition: From November 1 ,2019 to January 31 ,2020
- Details of the cancellation of treasury stock
(1) Class of shares to be cancelled: Common stock of the Company
(2) Number of shares to be cancelled: All of the shares acquired as stated in 2 above
(3) Cancellation date: February 14, 2020 (planned)
* The actual number of shares to be cancelled will be announced after
completing the acquisition of own shares stated in 2 above.
(Reference) Status of treasury stock as of September 30, 2019:
Total number of shares outstanding (excluding treasury stock): 1,885,429,653 shares
Total number of treasury stocks: 3,393,522 shares
Click below for a copy of the full press release
